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Abstract: TRPA1 is an ankyrin receptor of TRP family. It is mostly expressed in the small-
diameter nociceptors with cell bodies located in the dorsal roots, as well as in trigeminal, nodose 
and jugular ganglia. Recently, more and more information has been found in the literature on the 
role of TRPA1 in the realization of cold and pain sensitivity, and also in the formation and 
maintenance of inflammation. Subject to these data there is an increasing interest in finding and 
studying pharmacological agents able to selectively block the TRPA1 receptors and thereby 
reduce the severity of pain and inflammation. 
Using the molecular modeling techniques, we analyzed spectra of biological activity of a series of 
promising candidates for selective antagonists of TRPA1 ion channel in order to find potentially 
active compounds against pain and inflammation. 
Substances that showed in high throughput screening the percentage of the cellular calcium response 
inhibition above 50% - 3*SD maximum and its own agonistic activity less than 10% + 3*SD 
minimum were identified as hits. The value IC50 for hits was determined immediately after re-testing 
at 10 μM concentration and repeatedly after the determination of the leading chemical series.  
As the result of the studies, the biologically active molecules of leading chemical series have been 
confirmed. The research was partially supported by the grant of the President of the Russian 
Federation №MD-4711.2015.7  and МК-6135.2016.4. 
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Over the past 20 years there has been a revival of 
interest in the fundamental mechanisms of nociception 
[1, 2]. Recent advances in immunohistochemistry, 
neuropharmacology and neurophysiology contributed to 
new discoveries in the field of physiology and 
pathophysiology of pain. The conducted studies resulted 
in the discovery of new receptors and mechanisms of 
pain perception. The obtained information ensured the 
opportunity to create and apply new tools and methods 
for more effective and safe control over pain [3]. One of 
the modern methods of pain treatment is the use of 
various substances that can selectively block the 
receptors that directly perceive both pain stimuli and 
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inflammatory mediators. One of these receptors is an 
ankyrin receptor TRPA1. 
The TRPA1 is mostly expressed in the small-
diameter nociceptors with cell bodies located in the 
dorsal roots, as well as in trigeminal, nodose and jugular 
ganglia [1, 2, 4]. Some authors argue, according to the 
results of their research, for the increasing TRPA1 
expression in pathological conditions such as 
inflammation, neuropathy [5, 6, 7], by virtue whereof 
there has been an increase in interest in the TRPA1 as 
the receptor of pain stimuli [8, 9].  
Objective of the study was to confirm the 
activity of hits of the leading chemical series, 
obtained from high-throughput screening of a 
focused library. 
Materials and research methods. Embryonic 
human liver epithelial cells exogenously expressing 
the IPTG (isopropyl-β-D-1-thiogalactopyranoside)-
induced TRPA1 ion channel, were suspended in 
culture medium with 1 mM IPTG so as to obtain a 
concentration 8x105 cells/ml, which would amount 
20,000 cells per well. The resulting cell suspension 
was placed in a 384-well culture experimental dies 
with optical bottom with the use of automatic 
robotized stations Biomek FX or Biomek NX, 25 μg 
suspension in each well. 384-well dies were 
centrifuged at 200xg for 5 minutes. Further 
experimental dies with the cell suspension were 
transferred to an incubator at 37°C, 5% CO2. On the 
day of the experiment cells were immersed in Ca2+- 
sensitive dye, prepared by the manufacturer's 
instructions. Experimental dies filled with Ca2+- 
sensitive dye were incubated for 1 hour at a room 
temperature in a dark place. Further step was 
screening with FLIPR (Robotic High-Throughput 
Cellular Calcium Screening System).  
The TRPA1 ion channel was stimulated with 
agonist at EC80 concentration, which was 30 μM. 
For the inhibition of stimulated calcium response, we 
used the maximum inhibitory concentration of a 
control antagonist IC100, equal to 6 μM. FLIPR was 
turned on 30 minutes prior to the experiment to 
preheat its laser. We performed a signal test and 
adjusted the laser so as the base signal level was 
equal to 10,000 relative fluorescence units. 
To detect agonist activity of test substances 12.5 μl 
substance was added to each well of 384-well die 
according to the die scheme. Further, the experimental 
dies were screened with FLIPR. After incubation,  
12.5 μl TRPA1 ion channel agonist and allyl 
isothiocyanate (AITC) were added for 11 minutes to 
each well of 384-well experimental die, and the second 
FLIPR screening immediately started to determine the 
antagonists. 
The dependence of antagonist activity on 
concentration was analyzed for substances. IC50 value 
was determined from the obtained relation. The 
experimental data were analyzed with GraphPad Prizm 
(GraphPad Software, Inc., San Diego, CA). For the 
construction of concentration dependence the following 
equation was chosen: Y=Bottom curve plateau + 
(Upper plateau-Lower Plateau)/(1+10^((LogIC50-
X)*Curve slope)).  
Results of the study. The obtained results show 
that all previously discovered hits of leading chemical 
series have confirmed their activity towards the TRPA1 
ion channel (Table 1, Figure 1-3). 
Table 1 
Summary table with IC50 data for verifiable hits 
 
 
 
Substance IC50, μM Comments
3455-3246 36.76
3455-3273 11.82
3455-3281 22.51
3455-3320 13.22 partial antagonist
4606-1800 13.56
5628-0670 12.81
6040-4753 7.439 partial antagonist
E002-2494 0.9008
E002-2495 3.747
E002-2498 3.039
G857-0153 7.6
G721-0484 9.623 partial antagonist
C276-1460 46.74
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Figure 1.The concentration dependence of antagonist activity on the concentration for verifiable hits  
and control antagonist RR. Each concentration point is the average of two repetitions. Partial antagonists 
 
 
 
Figure 2.The concentration dependence of antagonist activity on the concentration for verifiable hits and control antagonist 
RR. Each concentration point is the average of two repetitions. Full antagonists 
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Figure 3.The concentration dependence of antagonist activity on the concentration for verifiable hits and control  
antagonist RR. Each concentration point is the average of two repetitions. Full antagonists 
 
Summary. As a result of molecular screening of 
biologically active molecules- candidates for selective 
antagonists of TRPA1 ion channel, it was found that all 
investigated hits of the leading chemical series 
confirmed their activity. Thus, these molecules can be 
recommended for further studies of their activity in the 
tests in vivo in laboratory animals.  
 
References 
1. Caspani O., Zurborg S., Labuz D., Heppenstall P.A. 
The contribution of TRPM8 and TRPA1 channels to cold 
allodynia and neuropathic pain. PLoS One. № 4(10) 
(2009): Р. 7383. [PMC] 
2. Krivoshapkin A.L. Physiologia of pain, Current 
concepts and mechanisms. Queen’s Medical Centre, Great 
Britain. http://www.painstudy.ru/matls/review/fizio.htm 
(date of the application 08.02.2016). [Full text] 
3. Tactics and emergency treatment of pain. 
Research and information material. Non-profit 
organization "Association of Moscow universities." 
Moscow, 2010. 266 p. [Full text] 
4. Trevisani M., Siemens J., Materazzi S. et al.  
4-Hydroxynonenal, an endogenous aldehyde, causes pain 
and neurogenic inflammation through activation of the 
irritant receptor TRPA1. Proc. Natl. Acad. Sci. USA.  
Vol. 104(33) (2007): P. 13519-13524.[PubMed] [PMC] 
5. Asai Y.A, Holt J.R., Geleoc G.S. A quantitative 
analysis of the spatiotemporal pattern of transient receptor 
potential gene expression in the developing mouse 
cochlea. J. Assoc. Res. Otolaryngol. Vol. 11(1) (2010):  
P. 27-37. [PMC] 
6. Jordt S.E, Bautista D.M., Chuang H.H., McKemy 
D.D., Zygmunt P.M., Högestätt E.D., Meng I.D., Julius D. 
Mustard oils and cannabinoids excite sensory nerve fibers 
through the TRP channel ANKTM1. Nature.  
Vol. 427(6971) (2004): P. 260-265. [PubMed] 
7. Matta J.A., Cornett P.M., Miyares R.L., Abe 
К.,Sahibzada N., Ahern G.P. General anesthetics activate a 
nociceptive ion channel to enhance pain and inflammation. 
Proc. Natl. Acad. Sci. USA. Vol. 105(25) (2008):  
P. 8784-8789. [PubMed] [PMC] 
8. McNamara C.R., D.M. Mandel- J. Brehm,  
C.R. J.A. Matta, P.M. Cornett, R.L. Miyares К. Abe,  
N. Sahibzada, Ahern Bautista G.P. TRPA1 mediates 
formalin-induced pain. Proc. Natl. Acad. Sci. USA.  
Vol. 104(33) (2007): P. 13525-13530.[PubMed] [PMC] 
9. Wei H., Hamalainen M.M., Saarnilehto M., 
Koivisto A., Pertovaara A. Attenuation of mechanical 
hypersensitivity by an antagonist of the TRPA1 ion 
channel in diabetic animals. Anesthesiology. Vol. 111(1) 
(2009): P. 147-154. [PubMed] [Full text] 
 
